title: Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma.
abstract: Standardized guidelines for the baseline evaluation and response assessment of primary CNS lymphoma (PCNSL) are critical to ensure comparability among clinical trials for newly diagnosed patients. The relative rarity of this tumor precludes rapid completion of large-scale phase III trials and, therefore, our reliance on the results of well-designed phase II trials is critical. To formulate this recommendation, an international group of experts representing hematologic oncology, medical oncology, neuro-oncology, neurology, radiation oncology, neurosurgery, and ophthalmology met to review current standards of reporting and to formulate a consensus opinion regarding minimum baseline evaluation and common standards for assessing response to therapy. The response guidelines were based on the results of neuroimaging, corticosteroid use, ophthalmologic examination, and CSF cytology. A critical issue that requires additional study is the optimal method to assess the neurocognitive impact of therapy and address the quality of life of PCNSL survivors. We hope that these guidelines will improve communication among investigators and comparability among clinical trials in a way that will allow us to develop better therapies for patients.
authors.affiliation: Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. abreyl@mskcc.org
authors.forename: Lauren E
authors.initials: LE
authors.lastname: Abrey
authors.forename: Tracy T
authors.initials: TT
authors.lastname: Batchelor
authors.forename: Andrés J M
authors.initials: AJ
authors.lastname: Ferreri
authors.forename: Mary
authors.initials: M
authors.lastname: Gospodarowicz
authors.forename: Elisa J
authors.initials: EJ
authors.lastname: Pulczynski
authors.forename: Emanuele
authors.initials: E
authors.lastname: Zucca
authors.forename: Justine R
authors.initials: JR
authors.lastname: Smith
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Korfel
authors.forename: Carole
authors.initials: C
authors.lastname: Soussain
authors.forename: Lisa M
authors.initials: LM
authors.lastname: DeAngelis
authors.forename: Edward A
authors.initials: EA
authors.lastname: Neuwelt
authors.forename: Brian Patrick
authors.initials: BP
authors.lastname: O'Neill
authors.forename: Eckhard
authors.initials: E
authors.lastname: Thiel
authors.forename: Tamara
authors.initials: T
authors.lastname: Shenkier
authors.forename: Fransesc
authors.initials: F
authors.lastname: Graus
authors.forename: Martin
authors.initials: M
authors.lastname: van den Bent
authors.forename: John F
authors.initials: JF
authors.lastname: Seymour
authors.forename: Philip
authors.initials: P
authors.lastname: Poortmans
authors.forename: James O
authors.initials: JO
authors.lastname: Armitage
authors.forename: Franco
authors.initials: F
authors.lastname: Cavalli
mesh_terms: D016543:Central Nervous System Neoplasms / Q000473:pathology* / Q000628:therapy*; D002986:Clinical Trials as Topic; D003072:Cognition Disorders / Q000209:etiology; D023381:Endpoint Determination; D017408:Guidelines as Topic; D006801:Humans; D007391:International Cooperation; D008223:Lymphoma / Q000473:pathology* / Q000628:therapy*; D011788:Quality of Life; D017741:Survivors